| CAS ID: | 284461-73-0 |
| Molecular Formula: | C21H16ClF3N4O3 |
| Molecular Weight: | 464.8 g/mol |
| Monoisotopic Mass: | 464.0863 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | SORAFENIB TOSYLATE | NEXAVAR | SORAFENIB | BAY 54-9085 | BAY 43-9006 | [11C]-Sorafenib |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31) | See All |
| InChI Key: | MLDQJTXFUGDVEO-UHFFFAOYSA-N | |
| Smiles: | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 26039995 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,mice | Fibrosis Disease | Liver fibrosis |
| Process I | |||
| Process II | HSCs activation | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting STAT3 | ||
Reference Record 2
| PubMed ID | 26572488 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Liver fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT01425216 | Disease | Keloid |
| Phase | Phase 2 | Status | Terminated |
| First Received | August 29, 2011 | Last Verified | October 18, 2016 |
| Sponsor | Tirgan, Michael H., M.D. | ||
| PubChem: | 216239 |
| ChEMBL: | CHEMBL1336 |